Articles tagged with Pancreatic Tumors
Researchers have discovered that T cells with a protein called CD26 on their surface are highly effective against aggressive solid tumors. These cells, previously overlooked in cancer immunotherapy, can resist apoptosis and repopulate after infusion, making them ideal for adoptive cell transfer therapy.
A study found that a subset of patients with bladder cancer is resistant to checkpoint inhibitors due to the tumor's immune desert microenvironment. Researchers identified a potential therapeutic strategy involving the inhibition of TGF-β activity, which may improve treatment outcomes for these patients.
Researchers at the University of Cincinnati have developed a targeted treatment that can prevent the spread of pancreatic cancer and protect the heart from damage. The treatment, which involves using an mTOR kinase inhibitor, has shown promise in reducing disease progression and cardiac impairment in patients with certain types of tumors.
Researchers at Salk Institute have discovered that modified vitamin D can reprogram the tumor environment, allowing Keytruda to invade and destroy pancreatic tumors. The clinical trial aims to combine vitamin D with immunotherapy for a potential game-changer in pancreatic cancer treatment.
A Stanford-led study discovered a specific mutation in the p53 gene that enhances its anti-tumor activity, creating a 'super tumor suppressor' that protects against pancreatic cancer. The researchers found that this mutant hyperactivates p53, leading to a surge of activity in downstream target genes.
Researchers at Mount Sinai Hospital discovered a genomic recipe in rare benign tumors that can regenerate insulin-producing human beta cells, potentially treating diabetes. The study's findings have the potential to develop new drugs that increase healthy beta cell mass.
Researchers discovered that targeting arginase 2, an enzyme involved in nitrogen metabolism, can curb the growth of pancreatic tumors, especially in obese individuals. The study suggests a novel approach to treating this deadly cancer, with potential for improved survival rates and therapeutic windows.
A study of 43 patients with pancreatic ductal adenocarcinoma found two preoperative factors strongly predictive of poor prognosis, regardless of tumor stage. These biomarkers, C-reactive protein/albumin ratio and prognostic nutritional index, may help plan treatment strategies to improve patient outcomes.
A new study demonstrates the feasibility and safety of HuMab-5B1, an antibody that targets the cancer antigen 19-9, found on pancreatic tumors and other malignancies. The treatment shows promise for better identifying tumors and directing treatment.
In a Phase 2 clinical trial, adding an experimental drug to standard chemotherapy improved progression-free survival by four months in patients with metastatic pancreatic cancer and high levels of hyaluronic acid in their tumors. The results suggest the benefit of the treatment is restricted to patients with this specific biomarker.
Researchers developed a biopolymer delivery system combining CAR T cells and STING agonists to eliminate tumors more effectively than CAR T cell therapy alone. The method improved targeting of solid tumors, reducing metastasis, and providing promising support for combined immunotherapy approaches.
Researchers at Fred Hutchinson Cancer Center developed a synthetic scaffold loaded with cancer-fighting T cells that shrank tumors more effectively than traditional injection methods. The scaffold created a homey environment for the T cells to survive and proliferate, outwitting self-defense chemicals released by tumors.
Researchers Melissa Skala and Matthew Vander Heiden won a $250,000 award to study the interaction between tumor cells and healthy supporting cells in pancreatic cancer. The project aims to create molecular changes that shut down the tumor's ability to scavenge nutrients, potentially leading to a new type of metabolic cancer therapy.
Researchers reprogram tumor blood vessels to block tumor growth and facilitate T cell arrival, improving cancer immunotherapy efficacy. A2V therapy inhibits metastasis and promotes anti-tumor immunity, which can be enhanced by PD-1 checkpoint blockade.
Australian scientists have discovered a novel strategy to treat pancreatic cancer by softening tumors with Fasudil before chemotherapy, doubling survival time and improving treatment efficacy. The sequential approach also slows cancer spread to other tissues.
Researchers at the University of Texas M. D. Anderson Cancer Center have identified arginine methyltransferase 1 (PRMT1) as a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC), a deadly form of pancreatic cancer with limited treatment options. PRMT1 plays a crucial role in tumor development and maintenance, and i...
Researchers identified PAK1 as a key player in aggressive tumor growth, fibrosis, and chemotherapy resistance. Targeting PAK1 may increase survival rates for patients with pancreatic cancer.
Researchers discovered two distinct fibroblast subtypes in the dense tumor-enveloping stroma of pancreatic ductal adenocarcinoma, which may be precisely targeted to improve treatment response. The first subtype produces high levels of alpha smooth muscle actin and is adjacent to neoplastic tumor cells.
Researchers found a previously unappreciated role for Abraxane in tumor immunology, suggesting ways to improve the drug and develop new combination treatments. Nab-paclitaxel enables macrophages to switch from immune-suppressing M2 cells back into M1 cells that amplify the body's effort to kill cancer cells.
Researchers at Arizona State University have developed a new diagnostic method for detecting pancreatic cancer early in its development by identifying extracellular vesicles with the surface protein EphA2. This technique shows promise for rapid and sensitive detection of various diseases based on unique EV signatures.
Blocking inflammation after radiation therapy led to improved survival in a mouse model of pancreatic cancer. The study found that a form of inflammation triggered by the tumor in response to treatment helps keep tumor cells alive, and that blocking this inflammation can slow tumor growth and prolong survival.
A new study reveals that inhibiting AXL signaling increases anti-tumor immune response, sensitizes tumors to radiation, and enhances efficacy of anticancer therapies. Aravive-S6 acts as a decoy receptor, binding Gas-6 to prevent AXL activation.
Researchers at Stanford University School of Medicine developed a receptor that attracted a key cancer-causing molecule called Gas6, slowing the progression of pancreatic and ovarian cancer in mice. The 'decoy receptor' showed a higher ability to reduce or stop cancer growth than other treatments did.
Researchers at Massachusetts General Hospital developed new methods for mapping and measuring solid stress within tumors, which may lead to novel treatment strategies. These methods revealed that solid stress and stored elastic energy may be different in primary and metastatic tumors.
Researchers discovered that low-dose chemotherapy regimens can prevent the secretion of proteins by fibroblast cells surrounding tumors, reducing the likelihood of tumor recurrence. Mice with breast or pancreatic cancer treated with these regimens survived longer than those receiving high-dose chemotherapy.
Researchers at CNIO have discovered CPEB4, a protein essential for melanoma cell survival and proliferation. The protein regulates the expression of factors unique to this tumour type, making melanomas more vulnerable to drugs targeting this pathway.
Researchers found that cancer tumors interfere with the liver's ability to cope with wasting and impair its response to immunotherapy. Massive caloric supplementation does not vanquish wasting, and immune therapy does not impair the tumor's ability to thrive.
The ESMO-MCBS scale has been successfully applied to rare tumor entities, revealing its potential to quantify the clinical benefit of certain drugs. The tool was particularly effective in highlighting the benefits of new immunomodulatory treatments.
Scientists from TUM discovered that pancreatic cancer cells create a 'niche' in the liver to grow and spread at an exceptionally early stage. This is facilitated by the protein TIMP1, which interacts with hepatic stellate cells to activate them and initiate metastasis.
A recent study has identified a potential biomarker for assessing pancreatic tumor grade, which could improve diagnostic techniques and treatment strategies. Annexin 6-expressing vesicles were found to support increased tumor growth and metastasis in pancreatic ductal adenocarcinoma tumors.
A new epigenetic test can diagnose the primary tumor responsible for metastasis in patients with Cancer of Unknown Primary (CUP), allowing for more specific treatments. This test, EPICUP, analyzes a patient's DNA to identify the type of cancer, resulting in improved survival rates.
A recent study published in Cell found that gamma delta T cells prevent tumor-fighting immune cells from attacking pancreatic tumors. This infighting makes immunotherapy less effective, with only 8% of people surviving five years after diagnosis.
Scientists at Johns Hopkins have discovered a drug combination that specifically targets the metabolic pathways of pancreatic cancer cells. By combining an experimental drug with metformin, researchers were able to shrink tumors by at least 50% in animal models, providing new evidence for treating this aggressive form of cancer.
Researchers at Tokyo Institute of Technology created a boron carrier system that uses albumin to target tumors, improving the delivery of boron in cancer treatment. The new system was tested on mice and showed promising results, with high concentrations of boron in tumors and low levels in healthy cells.
Researchers at Massachusetts General Hospital found a link between obesity and decreased response to chemotherapy in pancreatic cancer patients. Inhibiting the AT1 signaling pathway may be an effective strategy to overcome this obstacle.
Researchers have found that a combination of immunotherapy and FAK inhibitors can improve survival times in mice with pancreatic cancer. The study suggests that targeting fibrous tissue in tumors may render them more responsive to immune therapies.
Researchers developed a rapid screening technique to analyze human tumors transplanted into mice, identifying WDR5 as a new culprit in pancreatic cancer. The study found that WDR5 protects tumors from DNA damage and works with the previously known cancer-promoting gene Myc to help tumors thrive.
Researchers found that combining local radiation therapy with anti-cancer vaccines can increase the response rate for immunotherapy agents by boosting T cell infiltration into tumors. This combination may help physicians better treat many types of cancer and could potentially lead to improved outcomes.
Mayo Clinic researchers found that a combination of chemotherapy, radiation, and surgery can significantly improve survival rates for pancreatic cancer patients. Patients who received chemotherapy and/or radiation before surgery had better long-term outcomes than those who did not, with median survival times approaching four years.
Researchers discovered that high-pressure environments in solid tumors, fueled by hyaluronic acid, hinder drug delivery. Treatment with an enzyme that breaks down hyaluronic acid can restore vessel expansion and improve treatment outcomes for drug-resistant cancers.
Researchers found that orchestrated cell death mechanisms in pancreatic cancer can induce the growth of tumor cells by suppressing the immune system. Inhibiting these pathways may reverse immunosuppressive environments and enable T lymphocytes to attack tumors.
Researchers have developed an implantable device that delivers chemotherapy drugs directly to pancreatic tumors, showing promising results in slowing disease progression and shrinking tumors. The device uses a flexible film that conforms to the tumor shape and releases drugs locally, minimizing side effects and improving treatment outc...
A phase 1b clinical trial shows that an experimental therapy can control pancreatic cancer tumors well enough to make patients eligible for surgery. The treatment, PF-04136309, was found to be safe and effective when combined with chemotherapy.
Scientists developed triple-stage nanoparticles that improve tumor penetration and release cisplatin in acidic conditions, enhancing its efficacy while reducing toxic side effects. The delivery system demonstrated significant improvements in anti-tumor activity against various cancer models.
Researchers at Moffitt Cancer Center found that neutralizing the acidic tumor environment increases the efficacy of several immune-targeting cancer therapies. Sodium bicarbonate, combined with PD-1 or CTLA-4 inhibitors, reduced melanoma and pancreatic tumor growth in mice.
A new treatment advance has significantly lowered the risk of disease progression or death among patients with previously treated, advanced midgut neuroendocrine tumors. The novel drug Lutetium-DOTATATE has been found to offer an 80% reduced risk of disease progression or death compared to octreotide LAR.
A new implantable device delivers a toxic 4-drug cocktail directly to pancreatic tumors, limiting widespread side effects and increasing drug delivery by at least three times. This innovative approach shows promising results in halting tumor growth and shrinking tumors, offering new hope for patients with this deadly cancer.
A small minority of cancer cells in neuroendocrine tumors contribute to the overall growth and metastasis of the tumor. The discovery sheds light on the different functions of cancer cells, with implications for understanding tumor aggression.
A nanoparticle drug-delivery system that combines photodynamic therapy with a molecular therapy drug reduces tumor progression and metastasis in animal models. The treatment cuts off common treatment escape pathways, offering new possibilities for synchronized multidrug combination therapies.
Researchers found that metformin decreases inflammation and fibrosis in pancreatic cancer, which may be most prevalent in overweight and obese patients. The study also identified a potential biomarker for response to metformin treatment based on patient body weight.
The study found that everolimus improved progression-free survival by 52% and increased median progression-free survival by over seven months in patients with advanced, nonfunctional neuroendocrine tumors. The treatment was well-tolerated, with common side effects including aphthous ulceration, rash, diarrhea, fatigue, and infections.
Researchers have found that a protein called FAK plays a key role in the development of pancreatic neuroendocrine tumors. A two-drug combination has been shown to be more effective than everolimus alone in killing cancer cells and reducing tumor volume.
The University of Iowa has received a $10.67 million SPORE grant to research neuroendocrine tumors, which have seen a five-fold increase in incidence over three decades. The grant aims to develop new diagnostic and treatment approaches through analyzing gene expression profiles and identifying important mutations.
A study found genes associated with improved survival after surgery for pancreatic cancer patients. Detection of circulating tumor DNA in the blood predicted clinical relapse and poor outcomes.
A new study by the University of Pennsylvania School of Medicine has found that tumor cells associated with pancreatic cancer often behave like communities, working together to increase tumor spread and growth. The research suggests that interactions between subpopulations of tumor cell types contribute to metastatic progression.
Scientists at University College London have designed a chemical compound called MM41 that targets quadruplexes, faulty genes found in pancreatic cancers. The compound reduced tumor growth by 80% and prevented regrowth in mice, showing promise for treating pancreatic cancer.
Researchers developed new PET probes using labeled antibody fragments to visualize tumors in mice. These probes could provide more information about tumors and help doctors choose treatment options.
Researchers developed new PET probes composed of labeled antibody fragments that can detect pancreatic cancer tumors too small to be detected with conventional methods. These probes show promise for targeted imaging and tracking the delivery of drugs.
Researchers found that stereotactic body radiation therapy (SBRT) is safe and as effective as standard radiation treatment for certain patients with locally advanced pancreatic cancer. SBRT delivers high doses of radiation in a short period, resulting in reduced pain and improved quality of life. The treatment also allowed some patient...
Despite recent advances in understanding pancreatic cancer biology, researchers have made little progress in finding effective treatments. However, a new review suggests that immunotherapy combined with other treatments may significantly increase patient survival rates, and could lead to new therapeutic strategies.